Compounds > (4R,4aS,7aR)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one
Page last updated: 2024-12-11
(4R,4aS,7aR)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one
The compound you're asking about, **(4R,4aS,7aR)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one**, is a synthetic molecule with a complex structure. It doesn't have a widely recognized common name and its importance lies in its **potential as a pharmacological agent**.
Here's why it's interesting for research:
* **Novel Chemical Structure:** The molecule has a unique and complex structure, which sets it apart from other existing drugs. This complexity allows for potential interactions with various biological targets.
* **Potential Therapeutic Applications:** The molecule's structure suggests potential activity as a **modulator of G protein-coupled receptors (GPCRs)**. GPCRs are a large family of cell surface receptors involved in various physiological processes, including signal transduction, neurotransmission, and hormone regulation.
* **Preclinical Studies:** It's likely that preclinical studies have been conducted to evaluate the molecule's pharmacological profile and explore its potential therapeutic applications. These studies might have investigated its activity against specific diseases or conditions.
**However, without further information, it's difficult to say precisely why this specific molecule is being researched or what its specific potential applications might be.** To learn more about the molecule's specific importance, you would need to consult research papers or databases that mention it.
**Key takeaway:** This compound is a synthetic molecule with a unique structure that has potential for therapeutic applications, particularly in modulating GPCRs. Further research is needed to fully understand its pharmacological profile and potential clinical applications.
Cross-References
ID Source | ID |
PubMed CID | 5702239 |
CHEBI ID | 91813 |
SCHEMBL ID | 13050619 |
Synonyms (35)
Synonym |
KBIO1_000547 |
DIVK1C_000547 |
SPECTRUM_001645 |
IDI1_000547 |
SPECTRUM5_000976 |
BSPBIO_003154 |
KBIO2_004693 |
KBIOSS_002125 |
KBIO2_007261 |
KBIO3_002654 |
KBIOGR_001258 |
KBIO2_002125 |
SPECTRUM2_001547 |
NINDS_000547 |
SPECTRUM4_000639 |
SPECTRUM3_001587 |
SPBIO_001394 |
SPECTRUM1503262 |
HMS2093A17 |
HMS501L09 |
HMS1922O07 |
pharmakon1600-01503262 |
nsc758439 |
CCG-39325 |
NCGC00178236-02 |
BRD-A66559694-001-01-2 |
SCHEMBL13050619 |
AB00052339_02 |
CHEBI:91813 |
sr-05000001848 |
SR-05000001848-1 |
SBI-0051807.P002 |
(4r,4as,7ar)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one |
Q27163610 |
BRD-A66559694-001-03-8 |
Drug Classes (1)
Class | Description |
phenanthrenes | Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (5)
Assay ID | Title | Year | Journal | Article |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3
| High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6
| A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 13.20
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 13.20 (24.57) | Research Supply Index | 1.79 (2.92) | Research Growth Index | 4.99 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |